| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Carlsmed, Inc. Common Stock$12.93
+0.34 (+2.7%)
Market Cap
238.98 M
EPS
-1.15
P/E Ratio
-7.8 $
Value Trade
1.39 M
SEC Financials
Q1 2026Dilution Risk
Revenue
16.12 M
R&D Expenses
5.18 M
Operating CF
-13.01 M
Total Assets
118.77 M
Total Liabilities
26.52 M
Equity
92.25 M
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
97.02 M
Monthly Burn
4.34 M
Runway
19.6 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
199.02 K
52 Week Range
8.87 - 17.19
% held by Insiders
66.67 %
% held by Institutions
15.24 %
Enterprise Value
146.51 M
Total Shares
27.17 M
Short %
14.98 %
Float Shares
9.67 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CARL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CARL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-CARL
Aug 3, 2026▲ +2.7%today
Carlsmed Announces Favorable Reimbursement for aprevo® lumbar Procedures
Carlsmed, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a favorable reimbursement policy for aprevo® lumbar spinal fusion procedures. This decision, effective October 1, 2026, includes new MS-DRG assignments that will enhance hospital and patient access to the procedure. The CEO highlighted the importance of this policy in improving healthcare outcomes and reducing costs.
Read more →-CARL
Jul 22, 2026Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026
Carlsmed, Inc. announced it will release its second quarter 2026 financial results on August 5, 2026. The company, known for its AI-enabled personalized spine surgery solutions, will host a conference call and webcast to discuss the results. This event reflects the company's commitment to transparency with its investors.
Read more →-CARL
May 6, 2026▲ +10.3%on this news
Carlsmed® Reports First Quarter 2026 Financial Results
Carlsmed, Inc. reported a strong first quarter for 2026, achieving $16.1 million in revenue, a 58% increase from the previous year. The company raised its full-year revenue guidance to between $72 million and $77 million. Notably, clinical data published in the Global Spine Journal highlighted a significant reduction in revision rates for its product, aprevo®. The company is optimistic about its upcoming product launches and continued growth.
Read more →-CARL
Apr 29, 2026Carlsmed, Inc. To Participate in Upcoming Investor Conferences - April 28, 2026
Carlsmed, Inc. has announced that CEO Mike Cordonnier will participate in upcoming investor conferences. The company aims to improve healthcare outcomes through AI-enabled personalized spine surgery solutions. Live and archived webcasts of the presentations will be accessible on their investor relations website.
Read more →-CARL
Apr 28, 2026▼ -8%on this newsshared move
Carlsmed, Inc. To Participate in Upcoming Investor Conferences
Carlsmed, Inc. announced its participation in several upcoming investor conferences, including the Bank of America Global Healthcare Conference and the Jefferies Global Healthcare Conference. CEO Mike Cordonnier will engage in fireside chats and host one-on-one meetings with investors. These events aim to enhance investor relations and showcase the company's innovations in AI-enabled spine surgery solutions.
Read more →-CARL
Apr 14, 2026▲ +7.6%on this news
Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026
Carlsmed, Inc. has announced that it will report its first quarter 2026 financial results on May 5, 2026, after market close. The company will also host a conference call and webcast at 1:30 PM Pacific Time to discuss the results. This event reflects Carlsmed's commitment to transparency and investor engagement.
Read more →-CARL
Feb 26, 2026▲ +15.9%on this news
Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results
Carlsmed, Inc. reported strong financial results for Q4 and full year 2025, with revenues of $15.2 million and $50.5 million respectively, reflecting year-over-year growth of 61% and 86%. The company achieved a gross margin of 76.5% and improved operational efficiency by reducing lead times. The CEO highlighted significant advancements in patient outcomes through their AI-enabled spine surgery solutions.
Read more →-CARL
Feb 24, 2026Carlsmed, Inc. To Participate in the 2026 Canaccord Genuity Musculoskeletal Conference
Carlsmed, Inc. announced its participation in the 2026 Canaccord Genuity Musculoskeletal Conference, where CEO Mike Cordonnier will present on March 2, 2026. The conference will take place in New Orleans, LA, and a live webcast will be available for registered participants. This event highlights Carlsmed's commitment to advancing spine surgery through AI technology.
Read more →-CARL
Feb 12, 2026▼ -5.8%on this news
Carlsmed Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Carlsmed, Inc. has announced it will report its fourth quarter and full year 2025 financial results on February 25, 2026. The company, known for its AI-enabled personalized spine surgery solutions, will host a conference call and webcast at 1:30 PM Pacific Time on the same day. This event demonstrates the company's commitment to transparency with its investors.
Read more →-CARL
Feb 10, 2026Carlsmed Announces First aprevo® Bi-lateral Posterior Lumbar Interbody Fusion Procedure
Carlsmed, Inc. announced the successful completion of its first posterior lumbar spine surgery using the aprevo® Lumbar Bi-lateral Posterior System. This procedure, performed by Dr. CJ Kleck at the University of Colorado Hospital, marks a significant milestone for the company. Carlsmed aims to launch this technology commercially later this year, enhancing personalized spine surgery solutions.
Read more →-CARL
Jan 12, 2026▲ +13.8%on this news
Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025 Fourth quarter 2025 revenue of ~$15.2 million, representing ~61% growth over Q4 2024 2025 revenue of ~$50.5 million; representing ~86% grow
Carlsmed announced preliminary revenue figures for the fourth quarter and full year 2025, showcasing significant growth in both periods. Fourth quarter revenue reached approximately $15.2 million, a 61% increase compared to the same period in 2024. The total revenue for 2025 was about $50.5 million, reflecting an 86% growth year-over-year. The company emphasized the positive reception of its aprevo technology and aims for further expansion in 2026.
Read more →-CARL
Nov 6, 2025Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million
Carlsmed, Inc. reported impressive third-quarter 2025 financial results with a revenue of $13.1 million, marking a significant 98% growth year-over-year. The company raised its full-year revenue guidance to between $49 million and $50 million. Notable achievements include expanded gross margins and a substantial increase in surgeon user adoption. However, the company also faced rising operating expenses and reported a greater net loss compared to the previous year.
Read more →-CARL
Aug 28, 2025Carlsmed Reports Second Quarter 2025 Financial Results Q2'25 revenue of $12.1 million, 99% YOY growth Full year revenue guidance of $45.5M - $47.5M
Carlsmed, Inc. reported strong financial results for Q2 2025, with revenue reaching $12.1 million, representing a 99% increase year-over-year. The growth was attributed to higher adoption of its AI-enabled aprevo technology platform. The company is also positioned for further growth, targeting full-year revenue between $45.5 million and $47.5 million. However, net losses increased slightly compared to the same quarter last year, primarily due to rising operational expenses and development costs.
Read more →Competitive Position
How CARL ranks across every disease it competes inCompetitive Position is a premium feature
See how CARL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial